Technology Owner
University Hospital Hradec Králové
Palacký University of Olomouc

Zdeněk Zadák, Petr Klemera
Alena Tichá, Radomír Hyšpler
Tomáš Adam, David Friedecký
Hana Janečková, Alžběta Gardlo
Radana Karlíková

IPR Status
Czech patent applications (29.8.2017)
PV 2017-501 and PV 2017-502

Stage of Development
pilot study

Lucie Bartošová
+420 727 802 314


Breast cancer is the most common type of cancer in women and the second leading cause of death, after cardiovascular disease, in several countries. The early diagnosis of breast cancer is essential to ensure a high chance of survival for the affected women. Therefore, an important task is to provide high sensitivity diagnostic tools for early detection of breast cancer, possessing high specificity to avoid false positive results. X-ray mammography is today’s first line imaging modality. Several countries have implemented mammography screening programs aiming for early detection of the disease.

Description of the Invention
We have developed a breast carcinoma diagnostic test based on metabolomics analysis of apocrine sweat. The test was performed successfully with apocrine sweat samples from 53 apparently healthy women and 70 women with different stages of breast carcinoma. 20 markers were chosen and using mathematical-statistical methods we were able to classify them as healthy or as breast carcinoma suspect. The method sensitivity was determined in 97% (3% of false negative) and a specificity of 72% (28% false positive). We also found a baseline of apocrine sweat consisting in the combination of three markers, enabling the standardization of any volume or type of apocrine sweat sample for further analysis.

The test is non-invasive, easy to perform by women, without the need for a doctor’s visit. It can be repeated as often as women want without any burdening.  The high sensitivity of our test in comparison with a conventional x-ray mammography, which is only of ~75% (for radiographic dense breast tissue, which is more common in younger women, the sensitivity can even drop below 50%), offers a new possibility in non-invasive screening of breast carcinoma.

Potential Applications
Breast screening programs are increasingly controversial, especially regarding two points: the number of breast cancer deaths they avoid, and the problem of over-diagnosis and over-treatment. Therefore, some countries have already abandoned it. Thus our non-invasive diagnostic test comes with a new harmless opportunity of this dreaded disease.

Download in pdf here: technology summary – BREAST CANCER DIAGNOSTICS ENG

Comments are closed.